News
PRQR
1.710
0.00%
0.000
ProQR Presents Its Axiomer RNA Editing Technology At RNA Editing Summit
ProQR Therapeutics will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massachusetts. ProQR is a company dedicated to changing lives through transformative RNA therapies. Gerard Platenburg will present on June 20, 2024 at 2:00pm.
Benzinga · 4d ago
Weekly Report: what happened at PRQR last week (0610-0614)?
Weekly Report · 5d ago
Weekly Report: what happened at PRQR last week (0603-0607)?
Weekly Report · 06/10 11:54
Weekly Report: what happened at PRQR last week (0527-0531)?
Weekly Report · 06/03 11:57
Weekly Report: what happened at PRQR last week (0520-0524)?
Weekly Report · 05/27 12:03
Proqr Therapeuti: Report of foreign issuer
Press release · 05/23 17:22
Weekly Report: what happened at PRQR last week (0513-0517)?
Weekly Report · 05/20 11:54
Weekly Report: what happened at PRQR last week (0506-0510)?
Weekly Report · 05/13 12:09
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 05/10 14:24
ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital
Dow Jones · 05/10 14:24
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $2.5 Price Target
Benzinga · 05/10 14:14
ProQR Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 05/10 12:31
HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target
Benzinga · 05/10 12:21
Buy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial Footing
TipRanks · 05/10 11:57
ProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development Potential
TipRanks · 05/10 10:36
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/09 12:05
ProQR Therapeutics Reports Quarterly Financials
TipRanks · 05/09 11:58
ProQR GAAP EPS of -€0.09, revenue of €4.45M
Seeking Alpha · 05/09 11:50
PROQR THERAPEUTICS NV - EUR 102.7 MLN AS OF END OF Q1 PROVIDING RUNWAY INTO MID-2026
Reuters · 05/09 11:00
Buy Recommendation on ProQR’s Innovative RNA Editing Platform and Promising Clinical Prospects
TipRanks · 05/08 19:35
More
Webull provides a variety of real-time PRQR stock news. You can receive the latest news about Proqr Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About PRQR
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).